Making of a Unique Birth Control Vaccine against hCG with Additional Potential of Therapy of Advanced Stage Cancers and Prevention of Obesity and Insulin Resistance

TALWAR GP, RULLI SB, VYAS H, PURSWANI S, KABEER RS, CHOPRA P, SINGH P, ATREY N, NAND K, GUPTA JC

Journal of cell science & therapy

OMICS Publishing Group

Lugar: Los Angeles, CA ; Año: 2014 vol. 5 p. 159 - 166

Reviewed is the work which led to the development of a unique vaccine that prevents pregnancy in sexually active women without impairment of ovulation and block of their making normally their sex steroid hormones. Being given that hCG is not expressed by non-pregnant females, immunization with the vaccine is devoid of any crossreaction with any tissue of the body. It is totally reversible and women regained fertility on decline of antibodies. A recombinant vaccine has been developed which is highly immunogenic in mice. It is undergoing extensive toxicology under GLP conditions in rodents and a primate species, the marmosets, before resumption of clinical trials. Ectopic expression of hCG or its subunits takes place in a variety of cancers, particularly at advanced stage with adverse survival and poor prognosis. Anti-hCG antibodies exercise therapeutic action against such cancers as indicated by in vitro culture and in vivo studies in nude mice. Transgenic hCGbeta mice put on weight and manifest insulin resistance. Immunization of these mice with the recombinant hCG beta-LTB vaccine prevents obesity and insulin resistance.